Dr. Allen Hooper Sports Clinic at City Centre 207 – 399 Main Street Penticton, British Columbia Phone: 250-487-1455 Fax: 250-487-1453 PROLOTHERAPY What is prolotherapy? Prolotherapy, or proliferation therapy, is the injection of a solution to stimulate the growth of newcells to heal painful areas. Ligaments and tendons are the most common sites for injection. What do li
Microsoft word - curriculum vitae for richard lam.revised may2008.docCurriculum Vitae
Richard Y. Lam
Internship University of California, Los Angeles Division of Medical Oncology and Hematology. 1998-2001
Kaiser Foundation Hospital of West Los Angeles
Certification and Licensure
Licensing Examination, Steps 1-3, 1992-95 California Physicians and Surgeons License, 1996 Diplomat, American Board of Internal Medicine(Oncology), 2002 Honors and Awards
Phi Beta Sigma National Honor Society, UCLA 1987
Golden Key National Honor Society, UCLA 1988 Best Abstract, 1st Runner up. Western AUA, 2003. Super Doctor of Los Angeles. Los Angeles Magazine, 2008, 2010, 2011. Research Experience
“Genetics of Retinitis Pigmentosa,” Mentor: Bronwyn Bateman, MD, Jules Stein Eye Institute, UCLA, 1987-88. “Genetics of Sexual Reproduction in the Fruit Fly,” Mentor: Frank Laski, Ph.D., Molecular Biology Institute, UCLA, 1990. “Effects of Androgen Ablation on Co-Morbid Disease in Prostate Cancer Patients,” Mentor: Rowan Chlebowski, MD, Harbor-UCLA Medical Center, 1999. Publications
Lam, R., Chlebowski, R. “Tamoxifen to Treat Premenopausal Women with
Curti, M., Leung, M., Lam, R., Saeed, S., Gulati, P., Ni hara, Y. “Successful
Treatment of a Patient with Pure Red Cell Aplasia with Prednisone, Cyclosporine, and Antithymocyte Globulin.” Med Am, 2001.
Scholz, M., Lam, R., Brosman, S., Guess, B., “Calcitriol restores docetaxel
anticancer activity in men with androgen independent prostate cancer who
previously progressed on docetaxel. Proc West AUA, 2003.
Scholz, M., Lam, R., Brosman, S., Guess, B., “Extent of disease on bone scan,
baseline alkaline phosphatase, and 80% decline in PSA are the best
indicators predicting long-term survival in men with androgen independent
prostate cancer treated with ketoconazole.” Proc West AUA, 2003.
Scholz, M., Tril ing, T., Brosman, S., Guess, B., Johnson, H, Lam, R., “PSA nadir
greater than 0.1 on combined hormone blockade predicts the early
development of androgen independent prostate cancer in men with PSA
relapse after local therapy.” Proc West AUA, 2003.
Lam, R., Scholz, M, Guess, B, Trilling, T, “Oral bisphosphonates for the
prevention of androgen deprivation therapy-associated bone loss –
preliminary findings.” Proc ASCO, 2004.
Scholz, M., Jennrich, R., Strum, S., Brosman, S., Johnson, H., Lam, R.,
“Long-term outcome for men with androgen independent prostate
cancer treated with Ketoconazole and hydrocortisone.” J of Urology,
Lam, R., Scholz, M, Guess, B, Trilling, T, “Oral Bisphosphonates Fail to
Prevent Bone Loss from Androgen Deprivation Therapy in Men with
Prostate Cancer.” ASCO Multidisciplinary Prostate Conference, 2006.
Scholz, M.C., Jennrich, R.I., Strum, S.B., Johnson, H., Guess, B.G., Lam, R.Y.,
Intermittent Use of Testosterone Inactivating Pharmaceuticals Using
Finasteride Prolongs the Time Off Period. J Urol, 175:1673, 2006.
Mark C. Scholz; Lam, R ; Laurence Klotz., Letter to the Editor, re:
“Outcomes of Treatment vs Observation of Localized Prostate Cancer in
Elderly Men.” JAMA 297 (15):1651, 2007.
Tumor Board (Presenter and Discussant) Kaiser Permanente Bellflower. Weekly from October 1999 to April 2000 and November 2000 to February 2001. “Treatment Options for the Newly Diagnosed Prostate Cancer Patient.” Physician Education Lecture, Daniel Freeman Medical Center. April 4, 2002.
“Promising Experimental Drugs in Prostate Cancer.” Prostate Cancer Patient Support Group, Marina del Rey. November 2001. “Ketoconazole for Androgen Independent Prostate Cancer.” National Conference on Prostate Cancer, University of Southern California. October 4, 2002. “Management of Relapsed Prostate Cancer,” Prostate Cancer Patient Support Group, Mercy Hospital of Bakersfield. April 1, 2003. “Medical Options for Relapsed Prostate Cancer.” Prostate Cancer Patient Support Group, Holy Cross Medical Center. July 15, 2003. “Nizoral-Promising Results for a Treatment Often Overlooked.” National Conference on Prostate Cancer, Burbank Hilton Convention Center. September 7, 2003. “Management of Toxicities Related to Androgen Deprivation Therapy.” Southern California Radiological Society. January 23, 2004. “Approach to a Newly Diagnosed Prostate Cancer Patient.” Wel ness Community, Santa Monica, California. February 9, 2004. “Management of Toxicities Related to Androgen Deprivation Therapy.” Prostate Cancer Support Group, Marina del Rey. February 19, 2004. “Approach to a Newly Diagnosed Prostate Cancer Patient.” US Too Prostate Support Group, Las Vegas, June 17, 2004. “The Indications and Side Effects of Hormone Blockade.” Man-2-Man Prostate Support Group. Anaheim Memorial Hospital. July 7, 2004. “Tailoring Therapy for the Newly Diagnosed Patient.” Prostate Cancer Support Group, Marina del Rey. August 12, 2004. "Treatment Options for Relapsed Prostate Cancer.” US-Too, Phoenix. October 23, 2004. “New Options for Prostate Cancer.” Wel ness Community, Santa Monica, November 8, 2004. "Management of Relapsed Prostate Cancer." COPE-Support Group, Huntington Hospital. December 2, 2004. “Prostate Cancer Update.” Physician CME Lecture. Daniel Freeman Marina Hospital, May 6, 2005. “Hormone Resistant Prostate Cancer.” Wel ness Community Westlake. May 21, 2005. “Novel Therapies in Prostate Cancer.” Southwestern Prostate Health Conference, Phoenix. September 17, 2005. “New Treatment Options for Prostate Cancer.” Los Robles Community Hospital. November 2, 2005. “Systemic Therapies for Prostate Cancer.” COPE-Support Group, Huntington Hospital. February 6, 2006. “Addressing the Side Effects of Testosterone Inactivating Pharmaceuticals.” Prostate Cancer Research Institute Annual Conference, Cal State University Los Angeles. Sept 9, 2006. “Novel Therapies in Prostate Cancer.” Prostate Cancer Education and Awareness Conference. Southwestern University, Phoenix. Oct 28, 2006. “Role of Taxotere in Prostate Cancer.” Prostate Cancer Research Institute Annual Conference, Los Angeles. Sept 8, 2007. “What’s New in Prostate Cancer Management in 2008.” US-Too, Las Vegas. Jan 18, 2008. “Chemotherapy in Prostate Cancer,” Prostate Cancer Research Institute Annual Conference, Los Angeles. Sept 10, 2008. “Update on New Developments in Prostate Cancer: 2009,” Wel ness Community, Santa Monica, June 9, 2009. “Prostate Cancer Breakthroughs in 2009,” US-Too/American Cancer Society, Westlake Village, June 17, 2009. “What’s New in For Prostate Cancer in 2009,” The Informed Prostate Cancer Support Group, Moores Cancer Center, August 15, 2009. “Role of Chemotherapy in Prostate Cancer,” Prostate Cancer Research Institute Annual Conference, Los Angeles. September, 2009. “Management of Hormone Refractory Advanced Prostate Cancer,” The Prostate Forum of Orange County, January 10, 2010. Speakers Bureau
Cancer Committee, Daniel Freeman Memorial Hospital
Clinical Trials for Prostate Cancer
1. Phase III trial of Abiraterone 2. Phase II trial of MDV3100 3. Phase III trial of Ipilimumab 4. Phase II trial of Custirsen 5. Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer 6. Prevention of Gynecomastia with an Aromitase Inhibitor Femara 7. Androgen Replacement for Prostate Cancer Patients with Testicular Failure 8. The Prevention of Bone Loss with Oral Bisphosphonates 9. The Effect of Finesteride on Prolonging Time Off in Patients on Intermittent Hormone Blockade 10. Lack of Benefit of Local Therapy for Men with Preexisting AIPC 11. Prognostic Significance of Negative Biopsy after 12 Months of Hormone Blockade. 12. Addition of Bevacizumab to Taxanes Restores Anti-cancer Efficacy of Taxanes in Taxane-Refractory 13. Testosterone Replacement for Hypogonadal Men with Treated Prostate Cancer
____________________________________________________________ MINOXIDIL solución 2 mg/ml COMPOSICIÓN Conservación Minoxidil ………………………… 200 mg Caducidad Administración MODUS OPERANDI 1.- Pesar el polvo teniendo en cuenta la riqueza del producto. 2.- Pasar el polvo al vaso de precipitado y humedecerlo con una pequeña cantidad de alcohol